Engaging Stemness Improves Cancer Immunotherapy Publisher Pubmed

Summary: A review suggests targeting cancer stem cells could improve immunotherapy, enhancing treatment success. #CancerResearch #Immunotherapy

Dianatmoghadam H^{1, 2} ; Sharifi M¹ ; Salehi R^{1, 2} ; Keshavarz M³ ; Shahgolzari M⁴ ; Amoozgar Z⁵
Source: Cancer Letters Published:2023

Abstract

Intra-tumoral immune cells promote the stemness of cancer stem cells (CSCs) in the tumor microenvironment (TME). CSCs promote tumor progression, relapse, and resistance to immunotherapy. Cancer stemness induces the expression of neoantigens and neo-properties in CSCs, creating an opportunity for targeted immunotherapies. Isolation of stem-like T cells or retaining stemness in T clonotypes strategies produces exhaustion-resistance T cells with superior re-expansion capacity and long-lasting responses after adoptive cell therapies. Stem cells-derived NK cells may be the next generation of NK cell products for immunotherapy. Here, we have reviewed mechanisms by which stemness factors modulated the immunoediting of the TME and summarized the potentials of CSCs in the development of immunotherapy regimens, including CAR-T cells, CAR-NK cells, cancer vaccines, and monoclonal antibodies. We have discussed the natural or genetically engineered stem-like T cells and stem cell-derived NK cells with increased cytotoxicity to tumor cells. Finally, we have provided a perspective on approaches that may improve the therapeutic efficacy of these novel adoptive cell-based products in targeting immunosuppressive TME. © 2022 Elsevier B.V.